<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of primary prevention of cardiovascular disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of primary prevention of cardiovascular disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of primary prevention of cardiovascular disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles H Hennekens, MD, FACPM, FACC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Seres, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Freek Verheugt, MD, FACC, FESC</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sara Swenson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 25, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>In the United States and most resource-abundant countries, cardiovascular disease (CVD), which includes coronary heart disease (CHD), stroke, heart failure and peripheral artery disease, are leading causes of morbidity and mortality in adults [<a href="#rid1">1,2</a>]. Further, CVD is becoming the leading cause of death worldwide.</p><p>An overview of the primary prevention of CVD is presented here, including a discussion of the additive benefits of risk factor reductions through therapeutic lifestyle changes (TLCs) and adjunctive drug therapies of proven benefit. Secondary prevention of CVD, emerging risk factors, and determining individual risk of a patient without known CVD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a> and  <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease"</a> and  <a class="medical medical_review" href="/z/d/html/1546.html" rel="external">"Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">RATIONALE</span><span class="headingEndMark"> — </span>The following have been identified as major risk factors for cardiovascular disease (CVD). These factors can be modified with therapeutic lifestyle changes (TLCs) or treatment [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Smoking</p><p class="bulletIndent1"><span class="glyph">●</span>Overweight and obesity</p><p class="bulletIndent1"><span class="glyph">●</span>Unhealthy diet</p><p class="bulletIndent1"><span class="glyph">●</span>Physical inactivity</p><p class="bulletIndent1"><span class="glyph">●</span>Dyslipidemia</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension</p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes mellitus (considered in some guidelines as a coronary heart disease [CHD] risk equivalent)</p><p></p><p>Globally, up to 90 percent of the stroke burden may be attributable to modifiable risk factors, which can be substantially reduced by effective implementation of TLCs and adjunctive drug therapies of proven benefit. Additionally, in the descriptive INTERHEART study of patients from 52 countries, nine potentially modifiable factors accounted for over 90 percent of the population-attributable risk of a first myocardial infarction (MI) [<a href="#rid4">4,5</a>]. These included cigarette smoking, dyslipidemia, hypertension, diabetes, abdominal obesity, and psychosocial factors. Additional factors associated with lowered risks included regular physical activity, daily consumption of fruits and vegetables, and daily consumption of small amounts of alcohol. (See  <a class="medical medical_review" href="/z/d/html/2784.html" rel="external">"Cardiovascular benefits and risks of moderate alcohol consumption", section on 'Patients without known CVD'</a>.)</p><p>In descriptive data from a nationally representative survey, five modifiable risk factors for CVD (elevated cholesterol, diabetes, hypertension, obesity, and smoking) accounted for one-half of CVD deaths in United States adults aged 45 to 79 from 2009 to 2010 [<a href="#rid6">6</a>]. The preventable fraction of CVD mortality based on these risk factors was 54 percent for men and 50 percent for women.</p><p>The deleterious consequences of multiple risk factors are, at least, additive. In the Framingham Heart Study of over 5000 adults, those with five risk factors had a 10-year risk of a first CHD event of 25 to 30 percent, which is comparable to the absolute risk of a recurrent event for many patients who have survived a prior MI or occlusive stroke  (<a class="graphic graphic_figure graphicRef55353" href="/z/d/graphic/55353.html" rel="external">figure 1</a>) [<a href="#rid7">7</a>].</p><p>The majority of risk factors for a first CVD and stroke are modifiable by TLCs and adjunctive drug therapies of proven benefit [<a href="#rid8">8</a>]. In the United States, CVD mortality has been declining over the past several decades; however, due in part to increasing overweight and obesity as well as decreasing regular physical activity, the rates of decline have slowed since 2011 and are no longer evident [<a href="#rid9">9</a>]. It had been estimated that nearly half of the recent decline was due to earlier diagnosis and more aggressive treatment of modifiable risk factors, especially of lipids and blood pressure with adjunctive drug therapies, including statins, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, and beta adrenergic blockers [<a href="#rid10">10</a>]. The remaining half of the decline in CVD mortality is attributable to primary prevention, in particular TLCs.</p><p>The benefits of maintaining a healthy lifestyle in the primary prevention of CVD were apparent in observational data from the Nurses’ Health Study, a large, prospective cohort of over 121,701 female nurses in the United States followed for over 20 years. Women who maintained a desirable body weight, ate a healthy diet, exercised regularly, and did not smoke cigarettes experienced an 84 percent reduction in risk of clinical CVD events [<a href="#rid11">11</a>]. Further, in the Women's Health Study of 39,872 female health professionals in the United States, those practicing healthy lifestyle behaviors had a 55 percent lower risk of subsequent stroke [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H3"><span class="h1">MAJOR COMPONENTS</span></p><p class="headingAnchor" id="H4"><span class="h2">Healthy diet</span><span class="headingEndMark"> — </span>Individuals who self-select for a healthy diet have significantly lower risks of cardiovascular disease (CVD), including both coronary heart disease (CHD) and stroke. Components of a healthy diet include intakes of:</p><p class="bulletIndent1"><span class="glyph">●</span>Fruits and vegetables</p><p class="bulletIndent1"><span class="glyph">●</span>Fiber, including cereals</p><p class="bulletIndent1"><span class="glyph">●</span>Foods with a low glycemic index and low glycemic load</p><p class="bulletIndent1"><span class="glyph">●</span>Monounsaturated fat rather than trans fatty acids or saturated fats</p><p class="bulletIndent1"><span class="glyph">●</span>Omega-3 fatty acids (from fish or plant sources) (see <a class="local">'Omega-3 fatty acids'</a> below and  <a class="medical medical_review" href="/z/d/html/4555.html" rel="external">"Dietary fat", section on 'Polyunsaturated fatty acids'</a> and  <a class="medical medical_review" href="/z/d/html/5364.html" rel="external">"Healthy diet in adults", section on 'Protein-rich foods'</a>)</p><p></p><p>Observational studies have consistently shown that individuals consuming diets high in vegetables and fruits, such as the Mediterranean diet, have a reduced risk of CVD [<a href="#rid13">13</a>]. Individuals who consume more vegetables and fruits also tend to eat less meat and saturated fat. It is plausible, but unproven, that the apparent benefit may be due to specific compounds in vegetables and fruits, but the results of large-scale randomized trials have not generally supported this possibility. (See  <a class="medical medical_review" href="/z/d/html/5364.html" rel="external">"Healthy diet in adults", section on 'Mediterranean diet'</a>.)</p><p>A healthy diet and increased physical activity are therapeutic lifestyle changes (TLCs) to reduce risks of CVD that are supported by a large totality of evidence. Nonetheless, the United States may lead the world in overweight and obesity [<a href="#rid14">14</a>], and only 21 percent reach the daily minimum requirement for physical activity [<a href="#rid15">15-17</a>].</p><p>The US Preventive Services Task Force (USPSTF) recommends that adults with CVD risk factors receive behavioral counseling interventions to promote a healthy diet and increased physical activity [<a href="#rid18">18</a>]. CVD risk factors are defined as hypertension or elevated blood pressure, dyslipidemia, mixed or multiple risk factors, especially those with metabolic syndrome or an estimated 10-year CVD risk of 7.5 percent or greater.</p><p>Antioxidants as a component of a healthy diet show beneficial effects in basic research and observational studies, but randomized trials to detect the most plausible small to moderate benefits have generally shown no net benefit. Thus, the totality of evidence on supplements does not support their routine use for CVD prevention [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/5368.html" rel="external">"Vitamin intake and disease prevention", section on 'Antioxidants'</a>.)</p><p>The role of <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> supplementation in patients at risk for CVD is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5368.html" rel="external">"Vitamin intake and disease prevention", section on 'Cardiovascular disease'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Smoking avoidance and cessation</span><span class="headingEndMark"> — </span>Cigarette smoking remains both the leading avoidable cause of premature death worldwide as well as a major avoidable cause of morbidity. The totality of evidence indicates that the amount of cigarettes currently smoked increases morbidity and mortality from CVD, and benefits of cessation begin to appear after only a few months and reach that of the nonsmoker in several years, even among older adults [<a href="#rid20">20</a>]. Thus, for CVD, it is never too late to quit, whereas for cancer it is never too early. The risks of cancer are chiefly related to duration, and even 10 years after quitting the cancer risks remain about midway between those of the continuing and nonsmoker (See  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1504.html" rel="external">"Cardiovascular risk of smoking and benefits of smoking cessation"</a> and  <a class="medical medical_review" href="/z/d/html/6919.html" rel="external">"Secondhand smoke exposure: Effects in adults"</a>.)</p><p>All smokers should be counseled on a regular basis to quit. A number of approaches, including behavioral therapy, <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> replacement therapy, <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a>, and other pharmacologic therapies, are available [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Hypertension control</span><span class="headingEndMark"> — </span>Hypertension is a well-established risk factor for CVD, including morbidity and mortality from stroke, coronary heart disease (CHD), heart failure, and sudden death. (See  <a class="medical medical_review" href="/z/d/html/3850.html" rel="external">"Cardiovascular risks of hypertension"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Definition – Hypertension is defined in the 2017 American Heart Association/American College of Cardiology (AHA/ACC) guidelines as a systolic pressure ≥130 mmHg or a diastolic pressure ≥80 mmHg [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Goal blood pressure – Goal blood pressure may depend in part upon comorbidities (eg, diabetes, chronic kidney disease) and estimated cardiovascular risk; these issues are presented separately. (See  <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonpharmacologic measures – All patients with or without hypertension or elevated blood pressure should adhere to a healthy diet and increased physical activity. In addition, those with hypertension or elevated blood pressure should pay particular attention to nonpharmacologic TLCs which include weight reduction, salt restriction, and avoidance of excess alcohol intake. (See  <a class="medical medical_review" href="/z/d/html/3852.html" rel="external">"Overview of hypertension in adults", section on 'Nonpharmacologic therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pharmacologic therapy – Antihypertensive drugs are necessary for patients with persistent hypertension despite TLCs. Most patients will require multiple antihypertensive drug therapies to achieve their blood pressure goal. The choice of a specific agent for hypertension is presented separately. (See  <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a>.)</p><p></p><p class="headingAnchor" id="H3808484652"><span class="h2">Dyslipidemia</span><span class="headingEndMark"> — </span>Several large-scale randomized trials and their meta-analyses of statins in high-, moderate-, and low-risk primary prevention subjects without clinical evidence of CHD have demonstrated clinical benefits on CVD, including myocardial infarction (MI), stroke, and CVD death as well as total mortality [<a href="#rid23">23</a>].</p><p>Deciding who should be screened for dyslipidemia may vary based on different guidelines. This issue is discussed in detail separately. In contrast to blood pressure reduction where multiple therapies are commonly needed, statin therapy may be sufficient for the vast majority of patients requiring lipid modification. (See  <a class="medical medical_review" href="/z/d/html/4553.html" rel="external">"Screening for lipid disorders in adults"</a>.)</p><p>All primary prevention subjects, especially those with dyslipidemia, should be counseled to achieve and maintain a desirable body weight, engage in regular physical activity, and eat a healthy diet. Deciding when statin treatment should be initiated and the choice of adjunctive pharmacologic therapy of lipid disorders in primary prevention of CVD are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">"Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Physical activity</span><span class="headingEndMark"> — </span>Numerous observational studies have consistently shown that individuals who self-select for increased physical activity have lower morbidity and mortality from CHD  (<a class="graphic graphic_figure graphicRef81608" href="/z/d/graphic/81608.html" rel="external">figure 2</a>).</p><p>Regular physical activity is recommended in the early school years and throughout life. Common recommendations include moderate-intensity exercise for 150 minutes a week, vigorous-intensity exercise for 75 minutes a week, or an equivalent combination of these activities. Adults with limited exercise capacity due to comorbidities should stay as physically active as their condition allows [<a href="#rid15">15,16</a>]. Even modest amounts of regular physical activity, such as brisk walking for 20 minutes daily, are associated with significant benefits on risk of CHD [<a href="#rid17">17</a>]. Nonetheless, perhaps less than 20 percent of United States adults achieve this level of daily activity [<a href="#rid15">15,16</a>].</p><p>Although beneficial for all Americans, the USPSTF recommends that adults with CVD risk factors receive behavioral counseling interventions to promote a healthy diet and physical activity [<a href="#rid18">18</a>]. (See <a class="local">'Healthy diet'</a> above.)</p><p>The role of increased physical activity for primary prevention is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1510.html" rel="external">"Exercise and fitness in the prevention of atherosclerotic cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Weight loss</span><span class="headingEndMark"> — </span>In the United States and worldwide, overweight and obesity are important modifiable causes of premature deaths [<a href="#rid14">14</a>]. Overweight and obesity increase risk for several major risk factors for CVD, including hypertension, dyslipidemia, and insulin resistance, while weight loss has been shown to improve these parameters [<a href="#rid24">24-26</a>]. Data from large prospective cohort studies have consistently shown that individuals with higher body weights have a linear increase in morbidity and mortality from CHD, after appropriate adjustment for smoking and other confounders. (See  <a class="medical medical_review" href="/z/d/html/5370.html" rel="external">"Overweight and obesity in adults: Health consequences"</a>.)</p><p>In addition, in data from a random sample of the United States population from the National Center for Health Statistics, over 40 percent of adults aged 40 and over have metabolic syndrome, which is defined by the presence of three or more of the following: abdominal obesity, hypertriglycerides ≥150 mg/dL, high-density lipoprotein (HDL) &lt;40 mg/dL in men or &lt;50 mg/dL in women, systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg, fasting glucose ≥100 mg/dL. These individuals have a 10-year risk of a first CHD event of 16 to 18 percent, which is as high as many individuals who have already had an MI or stroke [<a href="#rid27">27</a>]. Such high-risk primary prevention subjects should be considered for pharmacologic or perhaps even surgical therapeutic options [<a href="#rid28">28</a>].</p><p>Selection of treatment for overweight subjects is based upon an initial risk assessment. All should be evaluated for their willingness and ability to adopt TLCs as well as other interventions of proven benefit. All individuals who are willing, ready, and able to lose weight should receive information about behavior modification, diet, and increased physical activity. (See  <a class="medical medical_review" href="/z/d/html/5372.html" rel="external">"Obesity in adults: Prevalence, screening, and evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">"Obesity in adults: Overview of management", section on 'Morbidity'</a> and  <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">"Obesity in adults: Overview of management", section on 'Mortality'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Management of type 2 diabetes</span><span class="headingEndMark"> — </span>The prevalence of type 2 diabetes has increased to epidemic proportions, largely due to the increase in overweight status and obesity. Mortality from diabetes results mainly from macrovascular complications of CHD, stroke, and peripheral artery disease. In addition, there are several major microvascular complications, especially retinopathy, nephropathy, and neuropathy.</p><p>To reduce macrovascular complications, multifactorial interventions are crucial, especially weight reduction, increased physical activity, and control of blood pressure, lipids, and glucose [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus"</a> and  <a class="medical medical_review" href="/z/d/html/3829.html" rel="external">"Treatment of hypertension in patients with diabetes mellitus"</a>.)</p><p>For microvascular complications, tight glycemic control reduces microvascular complications in both type 1 and type 2 diabetes mellitus. Tight glycemic control may also reduce risks of macrovascular complications in patients with type 1 and type 2 diabetes mellitus [<a href="#rid30">30-32</a>]. The target A1C levels in patients with diabetes should be tailored to the individual by weighing the benefits on morbidity and mortality against the risk of hypoglycemia. Details of glycemic control in patients with diabetes are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1751.html" rel="external">"Glycemic control and vascular complications in type 1 diabetes mellitus"</a> and  <a class="medical medical_review" href="/z/d/html/1760.html" rel="external">"Glycemic control and vascular complications in type 2 diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Aspirin</span><span class="headingEndMark"> — </span>Any decision to recommend <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> should be based upon an individual clinical judgment that includes an assessment of the magnitude of both the absolute CVD risk reduction and the absolute increase in major bleeding. Thus, prescription of aspirin should be based on consideration of benefits and risk, not age [<a href="#rid33">33</a>].</p><p><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> use for primary prevention of CVD is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/16291.html" rel="external">"Aspirin in the primary prevention of cardiovascular disease and cancer", section on 'Possible benefits'</a>.)</p><p class="headingAnchor" id="H2227941533"><span class="h2">Omega-3 fatty acids</span><span class="headingEndMark"> — </span>Omega-3 fatty acids significantly reduce triglycerides in a dose-dependent manner [<a href="#rid34">34</a>], but their independent benefits on clinical CVD are less clear, especially in those already treated with evidence-based doses of statins [<a href="#rid35">35</a>]. The role of this treatment in secondary prevention patients with hypertriglyceridemia is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4570.html" rel="external">"Hypertriglyceridemia in adults: Management", section on 'Marine omega-3 fatty acids'</a>.)</p><p>For patients without hypertriglyceridemia, the role of this treatment is uncertain, and practice varies. In a randomized trial in primary prevention of 25,871 adults without known cardiovascular disease (VITAL), after a median of 5.3 years, low-dose n-3 polyunsaturated fatty acid (PUFA; 1 g/day) did not reduce the primary endpoint of major cardiovascular events, which included both heart disease and stroke (hazard ratio [HR] 0.92, 95% CI 0.80-1.06) [<a href="#rid36">36</a>]. Among secondary outcomes, there was a reduction in total MI (HR 0.72, 95% CI 0.59-0.90), percutaneous intervention (HR 0.78, 95% CI 0.63-0.95), total CHD (HR 0.83, 95% CI 0.71-0.97), and death from MI (HR 0.50, 95% CI 0.26-0.97).</p><p class="headingAnchor" id="H12"><span class="h2">Benefits and risks of small amounts of daily alcohol</span><span class="headingEndMark"> — </span>In numerous case-control and prospective cohort studies, individuals who consume small amounts of alcohol have lower risks of morbidity and mortality from CHD than nondrinkers. The benefit seems related to the small amount of alcohol consumed rather than the type of alcoholic beverage. In some, but not the majority of analytic studies, individuals who consume red wine tend to have lower risks than those who consume other types of alcohol. This inconsistent finding may be due to other components in red wine or confounding by social class. A meta-analysis of nearly 600,000 individuals in 83 prospective studies who consumed alcohol found the lowest risk of all-cause mortality occurred at those whose alcohol intake was about 100 g/week (approximately six drinks/week) [<a href="#rid37">37</a>]. In this analysis, individuals self selection for the consumption of small amounts of daily alcohol intake had a decreased risk of mortality from MI but not from other causes. Thus, any benefit of daily alcohol intake for coronary artery disease must be weighed against the risks, which include hypertension, cerebral hemorrhage, and breast cancer. In addition, there have been significant increases in the United States in mortality from alcoholic cirrhosis [<a href="#rid38">38</a>].</p><p>The differences between consuming small and larger amounts of daily alcohol will mean the difference between avoidance and causation of premature death [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/2781.html" rel="external">"Overview of the risks and benefits of alcohol consumption"</a> and  <a class="medical medical_review" href="/z/d/html/2784.html" rel="external">"Cardiovascular benefits and risks of moderate alcohol consumption"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">ADDITIVE BENEFITS OF MULTIPLE RISK FACTOR REDUCTIONS</span></p><p class="headingAnchor" id="H6667172"><span class="h2">Lifestyle changes</span><span class="headingEndMark"> — </span>In primary prevention, modification of multiple major risk factors will produce reductions in risk of coronary heart disease (CHD) and stroke that are at least additive [<a href="#rid39">39</a>].</p><p>A European prospective cohort study of 2339 individuals, including 1507 men and 832 women aged 70 to 90 without cardiovascular disease (CVD) or cancer at baseline, assessed whether self-selection for a Mediterranean diet, being physically active, having small to moderate alcohol intake daily, and/or not smoking reduced all-cause and cause-specific mortality [<a href="#rid40">40</a>]. After a mean follow-up of 10 years, compared with those who adopted zero or one lifestyle change, those who self-selected for all four therapeutic lifestyle changes (TLCs) had a 67 percent lower risk of CVD mortality and a 65 percent lower risk of total deaths.</p><p>A prospective cohort study of over 20,000 Swedish men aged 45 to 79 without cancer, CVD, or CVD risk factors assessed whether individuals who self-selected for all of the five low-risk factors (healthy diet, moderate alcohol consumption, not smoking, being physically active, and having no abdominal adiposity) had lower risks of myocardial infarction (MI) [<a href="#rid41">41</a>]. During the 11-year follow-up, these men who practiced a healthy lifestyle had an 86 percent lower risk for MI (95% CI 0.04-0.43).</p><p>Similar results for primary prevention of stroke derived from the analyses of combined data from two large prospective cohorts, the Health Professionals Follow-up Study (43,685 men) and Nurses' Health Study (71,243 women), in which a low-risk lifestyle was defined as not smoking, body mass index (BMI) &lt;25 kg/m<sup>2</sup>, ≥30 minutes/day of moderate activity, modest alcohol consumption, and scoring in the top 40 percent on a healthy diet score [<a href="#rid42">42</a>]. Compared with participants having none, adults with all five low-risk factors had significantly lower risks of stroke (relative risks 0.31 in men and 0.21 in women).</p><p class="headingAnchor" id="H14"><span class="h2">Polypills</span><span class="headingEndMark"> — </span>Polypills to reduce CVD contain various combinations of medications such as statins, antihypertensive medications, and <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> [<a href="#rid43">43</a>]. From a population health standpoint, a polypill strategy is attractive because it seeks to minimize nonadherence, as it provides the major CV drug classes in one pill. Another potential advantage is decreased costs [<a href="#rid44">44</a>]. As such, they may be useful as a population-based strategy in resource-limited settings. The authors of TIPS-3 estimate that widespread use of the polypill may avert &gt;3 to 5 million CVD events globally [<a href="#rid45">45</a>].</p><p>Potential disadvantages include increased adverse effects, individual patient variability concerning the optimal combination of medications, and difficulty in titration with fixed dosing. In addition, while many polypill formulations include <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, the role of aspirin in primary prevention is controversial. Finally, it may not be usable if a patient has an allergy to any of the drugs in the combination pill. (See  <a class="medical medical_review" href="/z/d/html/16291.html" rel="external">"Aspirin in the primary prevention of cardiovascular disease and cancer", section on 'Possible benefits'</a>.) Polypills are not available commercially in the United States or Europe.</p><p>A 2017 systematic review of 13 randomized trials concluded that the effects of polypills on mortality or CVD events were inconclusive. However, most of the included trials evaluated changes in risk factors rather than CVD events [<a href="#rid46">46</a>]. In some but not all individual randomized trials, polypills increased adherence and decreased blood pressure and cholesterol but increased adverse events [<a href="#rid45">45,47-51</a>].</p><p>A 2021 individual-level meta-analysis examined three large RCTs of 18 162 individuals evaluating the effect of fixed dose polypills comprised of two antihypertensives and a low dose statin (with or without <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>) on primary CVD prevention. [<a href="#rid52">52</a>] During a median follow-up of 5 years, the primary CVD outcome (a composite of cardiovascular death, myocardial infarction, stroke, or arterial revascularization) occurred in 3 percent of individuals given the polypill compared with 4.9 percent in the control group (hazard ratio [HR] 0.62, 95% CI 0.53–0.73). GI side effects were more common in those taking the additional aspirin, although other bleeding was neither common nor significantly different in those treated with aspirin versus not.</p><p>The use of polypills has been proposed as a strategy to decrease CVD in underserved communities. In an open-label trial among 303 low-income adults in Alabama without CVD, 96 percent of whom were Black individuals, those randomized to receive a polypill containing <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> (10 mg), <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a> (2.5 mg), <a class="drug drug_general" data-topicid="9574" href="/z/d/drug information/9574.html" rel="external">losartan</a> (25 mg), and <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">hydrochlorothiazide</a> (12.5 mg) had a greater decrease in mean blood pressure (9 versus 2 mmHg, -7 mmHg difference, 95% CI -12 to -2), and LDL cholesterol levels (15 versus 4 mg/dL, -11 mg/dL difference, 95% CI -18 to -5) at one year compared with those in the usual care group [<a href="#rid50">50</a>]. Adherence at one year was 86 percent.</p><p class="headingAnchor" id="H3427901092"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119659.html" rel="external">"Society guideline links: Assessment of cardiovascular risk"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/111343.html" rel="external">"Society guideline links: Primary prevention of cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H232751309"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/83344.html" rel="external">"Patient education: Atherosclerosis (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/3440.html" rel="external">"Patient education: High cholesterol and lipids (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/1990.html" rel="external">"Patient education: Diet and health (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/2729.html" rel="external">"Patient education: Quitting smoking (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/1988.html" rel="external">"Patient education: Losing weight (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/3428.html" rel="external">"Patient education: Aspirin in the primary prevention of cardiovascular disease and cancer (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/4416.html" rel="external">"Patient education: High blood pressure in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/1743.html" rel="external">"Patient education: Type 2 diabetes: Overview (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Major risk factors</strong> – The following major risk factors for cardiovascular disease (CVD) are modifiable and should be considered in all adults: poor diet, smoking, hypertension, dyslipidemia, physical inactivity, overweight and obesity, and diabetes mellitus. (See  <a class="medical medical_review" href="/z/d/html/5364.html" rel="external">"Healthy diet in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">"Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"</a> and  <a class="medical medical_review" href="/z/d/html/1510.html" rel="external">"Exercise and fitness in the prevention of atherosclerotic cardiovascular disease"</a> and  <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">"Obesity in adults: Overview of management"</a> and  <a class="medical medical_review" href="/z/d/html/1751.html" rel="external">"Glycemic control and vascular complications in type 1 diabetes mellitus"</a> and  <a class="medical medical_review" href="/z/d/html/1760.html" rel="external">"Glycemic control and vascular complications in type 2 diabetes mellitus"</a> and  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multiple risk factor reduction</strong> – Reductions of multiple risk factors, through therapeutic lifestyle changes (TLCs) and adjunctive drug therapies of proven benefit, are likely to have at least additive benefits in the primary prevention of CVD. (See <a class="local">'Additive benefits of multiple risk factor reductions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of </strong><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> – The decision to recommend aspirin should be based upon an individual clinical judgment that includes an assessment of the magnitude of both the absolute CVD risk reduction and the absolute increase in major bleeding, not just age. (See  <a class="medical medical_review" href="/z/d/html/16291.html" rel="external">"Aspirin in the primary prevention of cardiovascular disease and cancer"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367:1747.</a></li><li><a class="nounderline abstract_t">Virani SS, Alonso A, Aparicio HJ, et al. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation 2021; 143:e254.</a></li><li><a class="nounderline abstract_t">Caldwell M, Martinez L, Foster JG, et al. Prospects for the Primary Prevention of Myocardial Infarction and Stroke. J Cardiovasc Pharmacol Ther 2019; 24:207.</a></li><li><a class="nounderline abstract_t">Feigin VL, Krishnamurthi RV, Parmar P, et al. Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990-2013: The GBD 2013 Study. Neuroepidemiology 2015; 45:161.</a></li><li><a class="nounderline abstract_t">Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937.</a></li><li><a class="nounderline abstract_t">Patel SA, Winkel M, Ali MK, et al. Cardiovascular mortality associated with 5 leading risk factors: national and state preventable fractions estimated from survey data. Ann Intern Med 2015; 163:245.</a></li><li><a class="nounderline abstract_t">Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121:293.</a></li><li><a class="nounderline abstract_t">Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45:3754.</a></li><li><a class="nounderline abstract_t">Sidney S, Quesenberry CP Jr, Jaffe MG, et al. Recent Trends in Cardiovascular Mortality in the United States and Public Health Goals. JAMA Cardiol 2016; 1:594.</a></li><li><a class="nounderline abstract_t">Capewell S, Beaglehole R, Seddon M, McMurray J. Explanation for the decline in coronary heart disease mortality rates in Auckland, New Zealand, between 1982 and 1993. Circulation 2000; 102:1511.</a></li><li><a class="nounderline abstract_t">Stampfer MJ, Hu FB, Manson JE, et al. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000; 343:16.</a></li><li><a class="nounderline abstract_t">Kurth T, Moore SC, Gaziano JM, et al. Healthy lifestyle and the risk of stroke in women. Arch Intern Med 2006; 166:1403.</a></li><li><a class="nounderline abstract_t">Sotos-Prieto M, Bhupathiraju SN, Mattei J, et al. Changes in Diet Quality Scores and Risk of Cardiovascular Disease Among US Men and Women. Circulation 2015; 132:2212.</a></li><li><a class="nounderline abstract_t">Hennekens CH, Andreotti F. Leading avoidable cause of premature deaths worldwide: case for obesity. Am J Med 2013; 126:97.</a></li><li><a class="nounderline abstract_t">Lewis SF, Hennekens CH. Regular Physical Activity: A 'Magic Bullet' for the Pandemics of Obesity and Cardiovascular Disease. Cardiology 2016; 134:360.</a></li><li><a class="nounderline abstract_t">Lewis SF, Hennekens CH. Regular Physical Activity: Forgotten Benefits. Am J Med 2016; 129:137.</a></li><li><a class="nounderline abstract_t">Manson JE, Hu FB, Rich-Edwards JW, et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med 1999; 341:650.</a></li><li><a class="nounderline abstract_t">US Preventive Services Task Force, Krist AH, Davidson KW, et al. Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors: US Preventive Services Task Force Recommendation Statement. JAMA 2020; 324:2069.</a></li><li class="breakAll">Hollar D, Hennekens CH. Randomized trials fail to fulfill promises of observational epidemiology. In: Antioxidants and Cardiovascular Disease, Tardiff JC, Bourassa MG (Eds), Springer, 2005. p.305.</li><li><a class="nounderline abstract_t">LaCroix AZ, Lang J, Scherr P, et al. Smoking and mortality among older men and women in three communities. N Engl J Med 1991; 324:1619.</a></li><li><a class="nounderline abstract_t">Gaballa D, Drowos J, Hennekens CH. Smoking Cessation: The Urgent Need for Increased Utilization of Varenicline. Am J Med 2017; 130:389.</a></li><li><a class="nounderline abstract_t">Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71:e13.</a></li><li><a class="nounderline abstract_t">Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388:2532.</a></li><li><a class="nounderline abstract_t">Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2014; 129:S102.</a></li><li><a class="nounderline abstract_t">Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393.</a></li><li><a class="nounderline abstract_t">Douketis JD, Macie C, Thabane L, Williamson DF. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond) 2005; 29:1153.</a></li><li><a class="nounderline abstract_t">Moore JX, Chaudhary N, Akinyemiju T. Metabolic Syndrome Prevalence by Race/Ethnicity and Sex in the United States, National Health and Nutrition Examination Survey, 1988-2012. Prev Chronic Dis 2017; 14:E24.</a></li><li><a class="nounderline abstract_t">Sherling DH, Perumareddi P, Hennekens CH. Metabolic Syndrome. J Cardiovasc Pharmacol Ther 2017; 22:365.</a></li><li><a class="nounderline abstract_t">Hennekens CH, Pfeffer MA, Newcomer JW, et al. Treatment of diabetes mellitus: the urgent need for multifactorial interventions. Am J Manag Care 2014; 20:357.</a></li><li><a class="nounderline abstract_t">Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643.</a></li><li><a class="nounderline abstract_t">Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:854.</a></li><li><a class="nounderline abstract_t">Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360:129.</a></li><li><a class="nounderline abstract_t">Kim K, Hennekens CH, Martinez L, et al. Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit-risk ratio, not age. Fam Med Community Health 2021; 9.</a></li><li><a class="nounderline abstract_t">Skulas-Ray AC, Kris-Etherton PM, Harris WS, et al. Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr 2011; 93:243.</a></li><li><a class="nounderline abstract_t">Aung T, Halsey J, Kromhout D, et al. Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals. JAMA Cardiol 2018; 3:225.</a></li><li><a class="nounderline abstract_t">Manson JE, Cook NR, Lee IM, et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med 2019; 380:23.</a></li><li><a class="nounderline abstract_t">Wood AM, Kaptoge S, Butterworth AS, et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet 2018; 391:1513.</a></li><li><a class="nounderline abstract_t">Termeie O, Fiedler L, Martinez L, et al. Alarming Trends: Mortality from Alcoholic Cirrhosis in the United States. Am J Med 2022; 135:1263.</a></li><li><a class="nounderline abstract_t">Leening MJ, Berry JD, Allen NB. Lifetime Perspectives on Primary Prevention of Atherosclerotic Cardiovascular Disease. JAMA 2016; 315:1449.</a></li><li><a class="nounderline abstract_t">Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA 2004; 292:1433.</a></li><li><a class="nounderline abstract_t">Akesson A, Larsson SC, Discacciati A, Wolk A. Low-risk diet and lifestyle habits in the primary prevention of myocardial infarction in men: a population-based prospective cohort study. J Am Coll Cardiol 2014; 64:1299.</a></li><li><a class="nounderline abstract_t">Chiuve SE, Rexrode KM, Spiegelman D, et al. Primary prevention of stroke by healthy lifestyle. Circulation 2008; 118:947.</a></li><li><a class="nounderline abstract_t">Castellano JM, Sanz G, Fernandez Ortiz A, et al. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality. J Am Coll Cardiol 2014; 64:613.</a></li><li><a class="nounderline abstract_t">Lonn E, Bosch J, Teo KK, et al. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation 2010; 122:2078.</a></li><li><a class="nounderline abstract_t">Yusuf S, Joseph P, Dans A, et al. Polypill with or without Aspirin in Persons without Cardiovascular Disease. N Engl J Med 2021; 384:216.</a></li><li><a class="nounderline abstract_t">Bahiru E, de Cates AN, Farr MR, et al. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst Rev 2017; 3:CD009868.</a></li><li><a class="nounderline abstract_t">Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ 2014; 348:g3318.</a></li><li><a class="nounderline abstract_t">Castellano JM, Sanz G, Peñalvo JL, et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol 2014; 64:2071.</a></li><li><a class="nounderline abstract_t">Indian Polycap Study (TIPS), Yusuf S, Pais P, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009; 373:1341.</a></li><li><a class="nounderline abstract_t">Muñoz D, Uzoije P, Reynolds C, et al. Polypill for Cardiovascular Disease Prevention in an Underserved Population. N Engl J Med 2019; 381:1114.</a></li><li><a class="nounderline abstract_t">Roshandel G, Khoshnia M, Poustchi H, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet 2019; 394:672.</a></li><li><a class="nounderline abstract_t">Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet 2021; 398:1133.</a></li></ol></div><div id="topicVersionRevision">Topic 7573 Version 77.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16731270" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33501848" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30563358" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prospects for the Primary Prevention of Myocardial Infarction and Stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26505981" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990-2013: The GBD 2013 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15364185" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26121190" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cardiovascular mortality associated with 5 leading risk factors: national and state preventable fractions estimated from survey data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1985385" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cardiovascular disease risk profiles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25355838" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27438477" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Recent Trends in Cardiovascular Mortality in the United States and Public Health Goals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11004141" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Explanation for the decline in coronary heart disease mortality rates in Auckland, New Zealand, between 1982 and 1993.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10882764" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Primary prevention of coronary heart disease in women through diet and lifestyle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16832006" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Healthy lifestyle and the risk of stroke in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26644246" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Changes in Diet Quality Scores and Risk of Cardiovascular Disease Among US Men and Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23331433" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Leading avoidable cause of premature deaths worldwide: case for obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27082238" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Regular Physical Activity: A 'Magic Bullet' for the Pandemics of Obesity and Cardiovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26247565" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Regular Physical Activity: Forgotten Benefits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10460816" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33231670" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors: US Preventive Services Task Force Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33231670" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors: US Preventive Services Task Force Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2030718" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Smoking and mortality among older men and women in three communities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27986524" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Smoking Cessation: The Urgent Need for Increased Utilization of Varenicline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29133356" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27616593" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Interpretation of the evidence for the efficacy and safety of statin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24222017" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11832527" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15997250" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28301314" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Metabolic Syndrome Prevalence by Race/Ethnicity and Sex in the United States, National Health and Nutrition Examination Survey, 1988-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28587579" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Metabolic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25181565" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Treatment of diabetes mellitus: the urgent need for multifactorial interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16371630" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9742977" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19092145" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Glucose control and vascular complications in veterans with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34952844" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit-risk ratio, not age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21159789" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29387889" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30415637" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29676281" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35636480" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Alarming Trends: Mortality from Alcoholic Cirrhosis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26999711" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Lifetime Perspectives on Primary Prevention of Atherosclerotic Cardiovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15383513" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25257629" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Low-risk diet and lifestyle habits in the primary prevention of myocardial infarction in men: a population-based prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18697819" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Primary prevention of stroke by healthy lifestyle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25104532" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21098469" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33186492" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Polypill with or without Aspirin in Persons without Cardiovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28263370" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24868083" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25193393" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A polypill strategy to improve adherence: results from the FOCUS project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19339045" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31532959" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Polypill for Cardiovascular Disease Prevention in an Underserved Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31448738" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34469765" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
